Daily Cosmetic Research Analysis
Analyzed 24 papers and selected 3 impactful papers.
Summary
Analyzed 24 papers and selected 3 impactful articles.
Selected Articles
1. Comparison of Dorsal Preservation Rhinoplasty and Dorsal Hump Reduction Rhinoplasty: A Systematic Review and Meta-Analysis of Postoperative Outcomes.
This systematic review and meta-analysis of nine studies (n=1,364) found dorsal preservation rhinoplasty and dorsal hump reduction yield comparable postoperative outcomes and safety profiles. Open approaches were more common than closed, and authors emphasize the need for further high-quality comparative trials.
Impact: Clarifies comparative effectiveness between two widely used rhinoplasty strategies, informing surgical planning and patient counseling. Provides a quantitative synthesis where practice patterns have rapidly evolved.
Clinical Implications: Both DPR and DHR are reasonable options; choose DHR when substantial structural reshaping is needed, while DPR may reduce certain complications without compromising outcomes. Surgeons should individualize technique based on anatomy and goals while awaiting more RCTs.
Key Findings
- Across 9 studies (n=1,364), DPR and DHR showed comparable postoperative outcomes.
- Safety profiles were similar between techniques based on reported complications.
- Open approaches were used more frequently than closed (56.6% vs 43.4%).
Methodological Strengths
- PRISMA-style systematic search with dual risk-of-bias tools (Newcastle–Ottawa, RoB 2.0).
- Quantitative synthesis across multiple comparative studies.
Limitations
- Heterogeneity in study designs and outcome measures; limited RCT data.
- Potential reporting bias and incomplete details (e.g., some metrics truncated in abstracts).
Future Directions: Prospective, CONSORT-compliant RCTs directly comparing DPR vs DHR, standardized outcome sets including PROMs, and longer-term functional and aesthetic follow-up.
BACKGROUND: Rhinoplasty is one of the most popular facial cosmetic procedures. Compared to dorsal hump reduction (DHR), a dorsal "preservation" rhinoplasty (DPR) approach has been developed to reduce the risk of complications and achieve an appealing dorsum. METHODS: An electronic search for articles comparing DHR to DPR was conducted on major databases. Results were screened through title/abstract and full-text stages. Included articles were extracted for information on demographics, surgical and patients reported outcomes, and for safety information. Newcastle-Ottawa scale and Cochrane's RoB 2.0 tool were utilized to assess the risk of bias in included article. RESULTS: Our search yielded (257) articles, of which nine articles describing a total of 1364 patients were fit for inclusion. The mean age was 30.59 ± 7.27 years, and majority were females (75.22%). Open surgical approach 772 (56.6%) was utilized more than closed approach 592 (43.4%). A mean difference of 0.03 [95% C.I. - 0.06-0.11, p = 0.52] (I CONCLUSION: DHR and DPR are comparable in effect, with each offering a promising outcome. DPR has a safety profile comparably beneficial to DHR, while DHR choice is appropriate in cases with substantial structure reshaping. Nevertheless, further research and clinical trials are necessary to establish the benefits of this alternative surgery. NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
2. Clinical Risk and Regulatory Oversight for Office-Based Cosmetic Procedures: A State-By-State Analysis.
A 50-state and DC review of statutes and board guidance found that delegation and supervision standards for office-based cosmetic procedures often do not scale with procedural risk. High-risk procedures were frequently subject to similar oversight as low-risk ones, enabling broad delegation.
Impact: Provides a comprehensive regulatory map that identifies systemic misalignment between risk and oversight, directly informing policy, credentialing, and patient safety strategies.
Clinical Implications: Clinicians and practices should implement internal, risk-stratified protocols for delegation and supervision regardless of jurisdictional minima, especially for injectables and ablative lasers. Professional societies can leverage these findings to advocate for harmonized, risk-based standards.
Key Findings
- Neuromodulator injections, dermal fillers, and ablative laser resurfacing were uniformly classified as medical practice.
- Oversight often failed to scale with risk; high-risk procedures commonly had delegation standards similar to low-risk procedures.
- Absence of procedure-specific language in multiple jurisdictions effectively enabled broad delegation.
Methodological Strengths
- Comprehensive, jurisdiction-wide review across all 50 states and DC.
- Risk categorization anchored to published complication profiles with a clear oversight taxonomy.
Limitations
- No linkage to clinical outcome data; policy analysis may not capture real-world enforcement.
- Dynamic regulatory environment and potential subjectivity in risk categorization.
Future Directions: Evaluate associations between oversight archetypes and real-world complication rates; develop consensus, risk-stratified model regulations and implementation toolkits.
BACKGROUND: Office-based cosmetic procedures are increasingly delegated by physicians to nonphysicians across a range of practice settings. These procedures vary substantially in technical complexity and complication risk. OBJECTIVE: To determine whether state-level scope-of-practice, delegation, and supervision standards for office-based cosmetic procedures scale with procedural risk. MATERIALS AND METHODS: Statutes, administrative codes, and medical, nursing, and cosmetology board guidance were reviewed for all 50 US states and the District of Columbia. Five office-based cosmetic procedures were categorized by risk based on published complication profiles: chemical peels, laser hair removal, neuromodulator injections, dermal filler injections, and ablative laser skin resurfacing. Jurisdictions were classified as aligned, delegated, fragmented, or inverted based on risk-oversight correspondence. RESULTS: Neuromodulator injections, dermal filler injections, and ablative laser resurfacing were uniformly classified as the practice of medicine. Delegation and supervision standards for higher-risk procedures were frequently comparable with those for lower-risk procedures. Delegated and fragmented archetypes predominated and consistently, risk-stratified oversight was uncommon. In multiple jurisdictions, absent procedure-specific regulatory language effectively permitted broad delegation in practice. CONCLUSION: State regulation of office-based cosmetic procedures often fails to align delegation and supervision standards with procedural risk, with implications for clinical practice and patient safety.
3. Poly-l-Lactic Acid Safety Over the Past 5-years: Analysis of US Food and Drug Administration Database Reports (2020-2025).
Analysis of 146 FDA MAUDE reports (222 events) shows nodules are the most common PLLA complication, while serious vascular events remain rare but occur in high-risk vascular territories. Missing data on dilution and injection location limit causal inferences.
Impact: Provides contemporary, device-level safety signals for a widely used biostimulatory filler, guiding risk communication, consent, and technique refinement.
Clinical Implications: Emphasize prevention and early management of nodules; avoid high-risk vascular zones and use safe-plane techniques. Standardize dilution and documentation to enhance safety monitoring and facilitate root-cause analysis.
Key Findings
- 146 unique reports comprising 222 adverse events were identified (2020–2025).
- Lumps/nodules were most frequent (38.7%), followed by hypersensitivity (12.2%), infection (11.3%), and swelling/induration (9.9%).
- Serious vascular events (5.4%), including blindness and skin necrosis, were rare and concentrated in high-risk vascular areas.
Methodological Strengths
- National device surveillance source capturing diverse real-world events.
- Granular categorization of event types with demographic context.
Limitations
- Underreporting and variable data completeness; lack of denominators precludes incidence estimation.
- No control for confounding factors such as injector experience or dilution protocols.
Future Directions: Link registry-based denominators to passive surveillance, and conduct prospective, standardized safety registries capturing dilution, plane, product lot, and vascular mapping.
BACKGROUND: Poly-l-lactic acid (PLLA) is a widely used biostimulatory filler which promotes neocollagenesis and provides gradual, long-lasting volumization. While its safe and effective use is well documented, its adverse event profile may continue to evolve alongside expanding indications, increasing patient demand, broader treatment areas, heterogeneous dilution practices, and variability in injector experience and technique. OBJECTIVE: To characterize contemporary complication trends with PLLA using the US FDA Manufacturer and User Facility Device Experience database. Data were extracted on patient demographics, complication type, injection location, and dilution (when available). Data were summarized descriptively. RESULTS: We identified a total of 146 unique reports, comprising 222 adverse events. The majority involved female patients (94%) with a median age of 50.5 years. Lumps/nodules were the most common complication (38.7%), followed by hypersensitivity reactions (12.2%), infection (11.3%), and swelling/induration (9.9%). Serious vascular events, including blindness and skin necrosis, were uncommon (5.4%) and most often involved high-risk vascular areas. CONCLUSION: In this Manufacturer and User Facility Device Experience analysis, lumps/nodules remain the most frequently reported complication of PLLA injections, while vascular events, though rare, continue to occur especially in high-risk anatomical regions. Variability and underreporting of dilution and injection location and technique limit assessment of contributory risk factors.